

November 13, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 023
BSE Code: 532926

National Stock Exchange of India Limited

Exchange Plaza, Bandra – Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: JYOTHYLAB

Dear Sir/ Madam,

Sub: Newspaper publication – Un-audited Financial Results of the Company for the quarter and half- year ended September 30, 2025

With reference to the captioned subject, we are enclosing herewith copies of newspaper advertisement published in Business Standard (English) and Navshakti (Marathi) today, i.e. November 13, 2025, pertaining to Un-audited Financial Results of the Company for the quarter and half-year ended September 30, 2025.

Further, the aforesaid information is also available on the website of the Company at www.jyothylabs.com.

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you,

Yours faithfully,

For Jyothy Labs Limited

Shreyas Trivedi

Head – Legal & Company Secretary

Encl.: as above

Jyothy Labs Limited

CIN: L24240MH1992PLC128651

‘Ujala House’, Ramkrishna Mandir Road,
Kondivita, Andheri (East), Mumbai 400059.
Tel: +91 022-6689 2800 | Fax: +91 022-6689 2805
info@jyothy.com | www.jyothylabs.com

Biocon expects debt rejig to give ₹300 cr booster to interest costs

Q&A As Biocon Biologics Ltd (BBL) charts its next phase of global expansion, Chief Executive Officer and Managing Director **Shreehas Tambe** outlines how the company is reshaping access, affordability, and growth in biosimilars. From California, in a video interview with **Sohini Das** and **Aneeka Chatterjee**, he talks of the ways in which BBL is working to stay ahead in competitive global markets. Edited excerpts:

Biocon Biologics is partnering California's CalRx initiative for affordable insulin. How significant is the tieup commercially, and does it indicate a broader shift toward government-linked procurement or value-based models in key markets?

■ The announcement with the California government for CalRx-branded insulin glargine is path-breaking. It is an arrangement that complements our flexible commercial platform. Through a partnership with Civica, a not-for-profit organisation, we enable direct distribution of insulin from the state to pharmacies, eliminating middlemen and making it affordable for Californians. California accounts for 20 per cent of America's insulin consumption, and this initiative opens a new, complementary channel for future state collaboration.

There are 50 states in the United States (US), and California is the first. We're already in discussion with several other states, as well as with partners like Civica and potentially TrumpRx, to explore similar initiatives. I would not call this a shift — it's not replacing our commercial channels. Rather, it's an example of the flexibility of our platform, which allows us to add another channel: Enabling direct-to-pharmacy access while continuing to serve existing ones.

Biocon has just settled structured debt obligations with Goldman Sachs and Kotak Mahindra Bank, and says this will cut interest costs from FY27. How much breathing room does this give Biocon Biologics

on the balance sheet?

■ We have been saying we will lighten the balance sheet and make it stronger. When we raised funds through a qualified institutional placement, we stated they would be used to retire structured debt. We have retired over ₹4,500 crore, closing out Goldman Sachs, Kotak Mahindra Bank, and soon Edelweiss. This will reduce interest costs by about ₹300 crore by FY27.

With debt easing and the business gaining traction, is the initial public offering (IPO) still on the table? What's the realistic timeframe now?

■ We do not have any new developments to report at this point. As you may recall, Kiran Mazumdar-Shaw (Biocon chief) had mentioned that the Biocon board had formed a committee to evaluate the best way to monetise Biocon's investment in biologics — whether through an IPO or another route. Until the committee completes its review and reports back to the Biocon board, we would not have any updates.

The launch of Denosumab is on track. Which launches do you see as the next growth engine, and how are you positioning against bigger global biosimilar rivals in the US, Europe?

■ At the close of FY25, we announced plans to launch five products in the US. Of these, four have been launched in the first two quarters, a major milestone, given the negotiations on intellectual property, settlements, and litigation involved. Previously, we had four products in the US over seven



years, but by FY26, we'll have five launches within 12-18 months of March 2025. The fifth product, our athlete peptide, is expected in the second half of next year. Though early, these launches position us strongly for sustained growth and competitive advantage.

The group has filed for semaglutide in Canada and Brazil. How significant are GLP-1 (glucagon-like peptide-1) products to Biocon's next phase of growth?

■ There is a sizable opportunity with semaglutide. Canada is expected to open up before other markets. Initially, there was an expectation that one of our Indian peers might enter sooner, but that seems to have been delayed somewhat. We already have the capability to develop and manufacture it.

But now, with our own commercial front in Canada through Biocon Biologics, we have a truly differentiated approach compared to many of our Indian peers. This sets us apart.

It also gives us an additional advantage because we are commercialising insulin in that region. So, alongside insulin, we can offer GLP-1 products through the same distribution channels, the same customers, and the same buying groups. This makes it a complementary offer that allows us to leverage existing relations.

You recently inaugurated a facility for oral solids in the US. Any plans to expand the manufacturing footprint?

■ We recently inaugurated our commercial manufacturing facility in Cranbury, New Jersey. Establishing it in the US was a strategic move. Being closer to the market, it provides logistical and procurement advantages. It's a sound business decision that strengthens our competitive position and supports long-term sustainability.

Given your partnership with Civica for insulin manufacturing in the US, are you exploring a similar local production model for semaglutide?

■ We have established a partnership with Civica to produce insulin domestically. Under this collaboration, we supply the drug substance, and Civica manufactures insulin in the US, for the US. This decision was made well before recent trade discussions. It was based purely on business rationale. Producing close to our patients and markets simply makes sense.

The same principle will guide our approach to semaglutide manufacturing. If it makes business sense to produce locally, based on demand and market dynamics, we will. Wherever there is a large consumption base, we aim to be close to our customers.

Tillman to invest ₹15,000 cr to set up Vizag data centre

SHINE JACOB
Chennai, 12 November

Andhra Pradesh has signed an agreement with New York-headquartered Tillman Global Holdings to develop a 300 megawatt (Mw) hyperscale data centre campus called TDGAP1 in Visakhapatnam for a proposed investment of ₹15,000 crore.

The project will be facilitated through the Andhra Pradesh Economic Development Board (APEDB) and strengthen Visakhapatnam's reputation as a digital infrastructure hub in the Indo Pacific, said a statement.

A memorandum of understanding (MoU) between the two sides sets a facilitation framework for time-bound development within 12 months, with APEDB coordinating investor support and inter-agency facilitation under applicable state and central government policies. The project will span about 40 acres and is expected to generate 200–300 direct jobs and 800–1,000 indirect jobs by 2028 through growth in allied services, logistics, Cloud networks, and ancillary units.

Tillman, a digital infrastructure company, will bring investment, technology, planning and design, and critical equipment for TDGAP1. All land allotments, incentives, and benefits will be undertaken by relevant state departments through due process, including participation in

applicable tender processes.

“Andhra Pradesh offers a compelling combination of coastal connectivity, progressive governance, and a rapidly expanding digital economy,” said Sachit Ahuja, co president, Tillman Global Holdings. “With TDGAP1, we aim to build a world class 300 MW campus in Visakhapatnam that anchors long term digital infrastructure, creates high quality jobs, and catalyses a broader ecosystem of services and innovation. We value the state's facilitation through APEDB and look forward to executing this project in a time bound manner”.

“This MoU underscores Andhra Pradesh's strategy to position Visakhapatnam as a premier data center hub,” said Nara Lokesh, the state's Minister for IT, Electronics and HRD. “The proposed Rs. 15,000 crore investment by Tillman Global Holdings will strengthen our digital backbone, generate direct and indirect employment for our youth, and attract allied investments across energy, networks, cloud, and services. The government will facilitate within policy to ensure swift, transparent progress.”

The development follows Google's announcement of a \$15 billion investment to establish an artificial intelligence data centre in Andhra Pradesh — its largest in India — in partnership with Adani Group and Airtel, including an international subsea gateway.

THE PROJECT WILL SPAN ABOUT 40 ACRES, AND IS EXPECTED TO GENERATE 200–300 DIRECT JOBS AND 800–1,000 INDIRECT JOBS BY 2028

Syrma plans to make printed circuit boards at Andhra plant: MD

AASHISH ARYAN
New Delhi, 12 November

Electronic manufacturing services (EMS) firm Syрма SGS plans to start the trial production of printed circuit boards (PCB) from its upcoming Andhra Pradesh manufacturing unit by December 2026 to facilitate the commercial production from the unit by March 2027, the company's Managing Director JS Gujral said.

“Once I start my trial production, I approach my customers for the approvals and other formalities,” Gujral told *Business Standard*.

The land for the plant had been provisionally allotted to the company and the process for registering it is underway, he said. The PCB manufacturing plant, for which Syрма SGS has received the central government's approval under the Electronics Component Manufacturing Scheme (ECMS), is located near Naidupeta in Tirupati district of Andhra Pradesh. The unit, spread over 7 lakh square feet, should be ready in the next 12-13 months, Gujral said.

“We expect to break ground for construction sometime in the next month. We have also



Syrma SGS is confident of crossing the 9% Ebitda target for FY26: MD JS Gujral

given the plans for approval. I am confident that we should be able to start construction very soon,” Gujral said.

The total investment in the plant is likely to be ₹1,595 crore and is expected to create 2,170 high-skill jobs. Overall, Syрма SGS is confident of crossing the 9 per cent earning before interest, taxes, depreciation, and amortisation (Ebitda) target for this financial year, Gujral said.

“What excites us are the new customers that we have onboarded, which are big-ticket size customers. They should be giving us the revenue from next year. We also expect our bracket of ₹100-crore customers going up to about 20 by next year from the 10 we have currently,” he said.

Google's \$15 bn AI hub to cater to user demand

AASHISH ARYAN
New Delhi, 12 November

Google expects an increase in demand from customers with the setting up of its \$15 billion artificial intelligence (AI) data hub in Visakhapatnam, said Matt Renner, president of global revenue at Google Cloud.

“There is a very progressive set of demands from firms in India, especially in the business-to-business and business-to-consumer spaces, when it comes to AI. We are seeing very broad and diverse demand from customers in India and trying to meet that with our infrastructure,” Renner said during a press conference on Wednesday.

Sovereign in-country investments, such as the one made by Google in Visakhapatnam, help the company assure its customers that their data will remain safe and within the geographical boundaries of their country, Renner said.

Google, he said, had “very advanced sovereign solutions” to meet any regulatory demands that Google Cloud's customers could have. In October this year, Google announced a \$15 billion investment over the next five years.

 Jyothy labs JYOTHY LABS LIMITED (CIN : L24240MH1992PLC128651) Registered Office: Ujala House, Ramakrishna Mandir Road, Kondivita, Andheri East, Mumbai 400059.						
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025						
(Rs. in lacs)						
Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from operations (net)	73,606	75,121	73,307	1,48,727	1,47,425	2,84,392
Net Profit before tax	11,869	12,753	13,559	24,622	26,809	48,955
Net Profit after tax	8,776	9,679	10,493	18,455	20,676	37,117
Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	8,734	9,636	10,470	18,370	20,630	36,947
Paid up Equity Share Capital	3,672	3,672	3,672	3,672	3,672	3,672
Reserves (excluding Revaluation Reserves)						1,34,589
Earnings Per Share of face value Re 1/- each						
Basic earnings per share (Rs)	2.39	2.64	2.86	5.03	5.63	10.11
Diluted earnings per share (Rs)	2.39	2.64	2.86	5.03	5.63	10.11
	Not	Not	Not	Not	Not	
	Annualised	Annualised	Annualised	Annualised	Annualised	Annualised

Notes :

- The above unaudited financial results of the Company for the quarter and half year ended September 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. Further, Ms. M. R. Jyothy, Chairperson and Managing Director of the Company is duly authorized by the Board of Directors of the Company to sign the aforesaid financial results for the quarter and half year ended September 30, 2025.
- The Board of Directors, at its meeting held on March 25, 2025, had approved the sale of the Company's entire equity stake in Jyothy Kallol Bangladesh Limited ('JKBL' or 'the Subsidiary') to Kallol Enterprise Limited ('KEL' or 'the Buyer'), for an aggregate consideration of Rs. 210 Lacs. This sale of investment has resulted into a loss of Rs. 370 lacs shown under "Exceptional Items" in the statement of profit and loss. JKBL ceased to be a subsidiary of the Company from March 25, 2025.
- Consequent to the sale of investment in the only subsidiary, with effect from March 25, 2025, the Company is now obliged to present only the standalone financial results for the quarter ended September 30, 2025. Accordingly, the comparative standalone segment information for the quarter and half year ended September 30, 2024 and the year ended March 31, 2025 was not subjected to limited review by the statutory auditors and has been compiled by the management, as the Company had then published consolidated segment results which were subject to such review.
- For more details on results, visit investor center section of the Company's website at www.jyothylabs.com and financial result under corporates section of Stock Exchange's Website at www.nseindia.com and www.bseindia.com.



For and on behalf of the Board of Directors

M. R. Jyothy
Chairperson and Managing Director
DIN : 00571828

SPECIAL WINDOW FOR RE-LODGEMENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

As mandated by SEBI a 'Special Window' has been allowed from July 07, 2025 to January 06, 2026 to facilitate re-lodgement of physical share transfer request that were originally lodged before April 1, 2019 but were rejected / returned due to deficiencies. Investors who missed the earlier cut-off of March 31, 2021, are encouraged to utilise this special window and submit the requisitie documents to the Company / Company's RTA- MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited).



Svatantra Microfin Private Limited				
Regd. Office: Sunshine Tower, Level 20, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400013				
Web.: www.svatantramicrofin.com Email: secretariat@svatantra.adityabirla.com Tel: + 912261415900 CIN: U74120MH2012PTC227069				
Extract of Statement of unaudited financial results for the quarter and half year ended 30 September, 2025				
[Regulation 52 (8), read with Regulation 52 (4), of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015")]				
(Rs. In Lakhs except per share data & ratios)				
Sr. No.	Particulars	Standalone		
		Quarter ended		Year ended
		30 September 2025	30 September 2024	30 September 2025
		(Unaudited)	(Unaudited)	(Unaudited)
		(Audited)		(Audited)
1	Total Income from Operations	43,607	43,759	82,907
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	6,523	7,191	9,724
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	6,523	7,191	9,724
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	4,847	5,360	7,206
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	4,910	5,454	7,234
6	Paid up Equity Share Capital	62,689	25,205	62,689
7	Reserves (excluding Revaluation Reserve)	279,516	54,358	279,516
8	Securities Premium Account	272,276	4	221,020
9	Net worth (including Compulsory Convertible Non-Cumulative Preference Shares)	342,205	255,063	342,205
10	Paid up Debt Capital / Outstanding Debt	564,482	567,755	564,482
11	Outstanding Redeemable Preference Shares	-	-	-
12	Debt Equity Ratio	1.65	2.23	1.65
13	Earnings Per Share (of Rs. 10/- each)			
1	Basic:	0.77	1.05	1.15
2	Diluted:	0.77	1.04	1.15
14	Capital Redemption Reserve	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA
Note: a) The above standalone financial results for the quarter and half year ended 30th September 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 07 November 2025 and 12 November 2025 respectively.				
b) The above is an extract of the detailed format of quarterly Financial Results filed with the BSE Limited under Regulation 52 of the SEBI Listing Regulations, 2015. The full format of the quarterly financial results is available on the website of the BSE Limited (www.bseindia.com) and on the Company's website (https://investors.svatantramicrofin.com/regulation-52-financial-results-and-disclosure).				
c) For the other line items referred in Regulation 52(4) of the SEBI Listing Regulations, 2015, pertinent disclosures have been made to the BSE Limited and can be accessed on the website of the BSE Limited (www.bseindia.com) and on the Company's website (https://investors.svatantramicrofin.com/regulation-52-financial-results-and-disclosure).				
By order of the Board of Directors For Svatantra Microfin Private Limited				
Sd/- Place : Mumbai Date: 12 November 2025				
Ananyashree Birla (Director) DIN: 06625036				

नव शक्ति १७
marathi.freepressjournal.in

ASHIANA AGRO INDUSTRIES LIMITED Reg. Office: No.34, Andal Nagar, Baluchetty Chatram, Kancheepuram Taluk, Kancheepuram Distt.- 631551 (Tamil Nadu) Tel No.: +91-44-28344820, Website: www.aail.in Extract of Standalone Unaudited Financial Results for the Quarter and Six Months Ended 30th September, 2025							
Sl. No.	Particulars	Quarter Ended			Six Months Ended		Rs. in Lakhs
		30.09.2025		30.09.2024	30.09.2024		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations Including Other Income (Net)	29.71	22.27	26.66	51.98	46.03	96.36
2	Net Profit/(Loss) for the period (Before Tax, Exceptional Items and / or Extraordinary Items)	2.17	(0.53)	5.71	1.64	6.64	11.36
3	Net Profit / (Loss) for the period before Tax (after Exceptional Items and / or Extraordinary Items)	2.17	(0.53)	5.71	1.64	6.64	11.36
4	Net Profit / (Loss) for the period after Tax (after Exceptional Items and / or Extraordinary Items)	1.77	(0.53)	1.15	1.24	2.08	8.50
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)	1.77	(0.53)	1.15	1.24	2.08	8.50
6	Paid up Equity Share Capital (Face Value of Rs.10/- per share)	460.00	460.00	460.00	460.00	460.00	460.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of previous year	-	-	-	-	-	201.27
8	Earning Per Share (EPS) (in Rs.) (Face Value of Rs.10/- each)						
	(a) Basic and diluted EPS before Extraordinary Items	0.04	(0.01)	0.03	0.03	0.05	0.18
	(b) Basic and diluted EPS after Extraordinary Items	0.04	(0.01)	0.03	0.03	0.05	0.18

Note: 1) The above results have been reviewed by the Audit Committee/ subject to limited review by the statutory auditors of the company and approved by the Board of Directors in their meeting held on November 12, 2025.

2) This statement has been prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

3) The above is an extract of the detailed format of the Standalone Unaudited Financial Results for the Quarter and Six Months ended September 30, 2025 filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Six months ended September 30, 2025 are available on website of their Stock Exchange at www.bseindia.com and also on the Company's website at www.aail.in.

For Ashiana Agro Industries Limited
Pavan Kumar J.

Whole Time Director
 DIN: 0243890

Place : Chennai
 Date : 12.11.2025





INDEF MANUFACTURING LIMITED

Corporate Office: 501-504, Shelton Cubix, Sector 15, Plot 87, CBD Belapur,
Navi Mumbai 400 614.

Registered Office: Bajaj Bhavan, 2nd Floor, 226, Nariman Point, Mumbai-400021.

Ph: +91 022-45417309 / 06 Email: cs1@indef.com

URL: www.indef.com CIN: L29308MH2022PLC390286



Extract of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Half Year Ended September 30, 2025

(Rs. In Lakhs)

SN NO	PARTICULARS	STANDALONE				CONSOLIDATED			
		Quarter ended	Half Year Ended	Year ended		Quarter ended	Half Year Ended	Year ended	
		30-Sept-25	30-Sept-24	30-Sept-25	31-Mar-25	30-Sept-25	30-Sept-24	30-Sept-25	31-Mar-25
		Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	5064.89	4860.96	9410.02	19369.43	5200.68	4860.96	9700.8	19559.55
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)¶	805.24	1120.03	1587.36	4204.68	742.23	1116.49	1499.18	4195.05
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)¶	805.24	1120.03	1587.36	4204.68	742.23	1116.49	1499.18	4195.05
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	670.07	1131.07	1256.52	3423.92	625.95	1128.42	1191.16	3416.03
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	668.20	1127.42	1252.78	3427.38	624.08	1124.77	1187.42	3419.50
6	Equity Share Capital	320.00	320.00	320	320	320	320	320	320
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet	-	-	-	24978.21	-	-	-	24970.33
8	Earnings Per Share (of Rs. 1.00 each) (for continuing and discontinued operations) - Basic & Diluted¶¶	2.09	3.53	3.93	10.70	1.96	3.53	3.72	10.68

NOTE:

1. The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. The above is an extract of the detailed format of Quarter and Half year ended Un-Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarter and Half year ended Un-Audited Financial Results are available on the websites of www.bseindia.com; www.nseindia.com and also on Company's website at www.indef.com and can be accessed by scanning below Quick Response (QR) Code.

2. Previous quarter / year figures have been appropriately recasted, regrouped and reclassified wherever necessary to confirm to the current year presentations.

3. #Company does not have any exceptional and extraordinary items to report for the above period.

4. ##EPS is not annualised for the quarter ended September 30,2025 and half year ended September 30, 2025.

Place: Mumbai

Date: November 12, 2025



On behalf of Board of Directors
of Indef Manufacturing Limited

Sd/-
Shekhar Bajaj
Chairman
DIN-00089358



Jyothy labs

ज्योती लॅब्स लिमिटेड

सीआयएन : एल२४२४०एमएच१९१२पीएलसी१२८६५१
नोंदणी कार्यालय : उजाला हाऊस, राम कृष्ण मंदिर रोड, कोंडीविटा, अंधेरी (पू), मुंबई - ४०० ०५९.

३० सप्टेंबर, २०२५ रोजी समाप्त तिमाही आणि अर्धवर्षाकरिता वित्तीय निष्कर्षांचा अहवाल

तपशील	तिमाही समाप्ती			अर्धवर्ष समाप्ती		वर्ष समाप्ती
	३०.०९.२०२५	३०.०६.२०२५	३०.०९.२०२४	३०.०९.२०२५	३०.०९.२०२४	३१.०३.२०२५
	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	लेखापरीक्षित
प्रवर्तनामधून एकूण उत्पन्न (निव्वळ)	७३,६०६	७५,१२१	७३,३०७	१,४८,७२७	१,४७,४२५	२,८४,३९२
कर पूर्व निव्वळ नफा	११,८६९	१२,७५३	१३,५५९	२४,६२२	२६,८०९	४८,९५५
कर पश्चात निव्वळ नफा	८,७७६	९,६७९	१०,४९३	१८,४५५	२०,६७६	३७,११७
सदर कालावधीसाठी सर्वसमावेशक एकूण उत्पन्न (सदर कालावधीसाठी नफा समाविष्ट (कर पश्चात) आणि अन्य सर्वसमावेशक उत्पन्न (कर पश्चात))	८,७३४	९,६३६	१०,४७०	१८,३७०	२०,६३०	३६,९४७
भरणा झालेले समभाग भांडवल	३,६७२	३,६७२	३,६७२	३,६७२	३,६७२	३,६७२
राखीव (पुनःमुल्यांकित राखीव वगळून)						१,३४,५८९
दर्शनिमूल्य प्रत्येकी रु. १ च्या प्रती भाग उत्पन्न						
प्रती भाग मुलभूत उत्पन्न (रु.)	२.३९	२.६४	२.८६	५.०३	५.६३	१०.११
प्रती भाग सौमिकृत उत्पन्न (रु.)	२.३९	२.६४	२.८६	५.०३	५.६३	१०.११
	वार्षिक नाही	वार्षिक नाही	वार्षिक नाही	वार्षिक नाही	वार्षिक नाही	वार्षिक

नंती : १. कंपनीच्या ३० सप्टेंबर, २०२५ रोजी समाप्त तिमाही आणि अर्धवर्षाच्या उपरोक्त अलेखापरीक्षित वित्तीय निष्कर्षांचे लेखापरीक्षण समितीद्वारे पुनरावलोकन करण्यात आले आणि कंपनीच्या संचालक मंडळाने त्यांच्या १२ नोव्हेंबर, २०२५ रोजी झालेल्या सभेमध्ये मंजूर केले. पुढे, मिस. एम. आर. ज्योती, कंपनीचे अध्यक्ष आणि व्यवस्थापकीय संचालक, ३० सप्टेंबर, २०२५ रोजी समाप्त तिमाही आणि अर्धवर्षाच्या उपरोक्त वित्तीय निष्कर्षांवर स्वाक्षरी करण्यासाठी कंपनीच्या संचालक मंडळाद्वारे योग्य पद्धतीने अधिकृत आहेत.

२. २५ मार्च २०२५ रोजी झालेल्या संचालक मंडळाच्या बैठकीत, ज्योती कल्लोल बांगलादेश लिमिटेड ('जेकेबीएल' किंवा 'उपकंपनी') मधील कंपनीचा संपूर्ण इक्विटी हिस्सा कल्लोल एंटरप्राइझ लिमिटेड ('केईएल' किंवा 'खरेदीदार') ला एकूण २१० लाख रुपयांच्या मोबदल्यात विकण्यास मान्यता दिली होती. गुंतवणुकीच्या या विक्रीमुळे नफा आणि तोटाच्या विवरणपत्रात 'अपवादात्मक बाबी' अंतर्गत दर्शविलेले ३७० लाख रुपये इतके नुकसान झाले आहे. जेकेबीएल दिनांक २५ मार्च २०२५ पासून कंपनीची उपकंपनी म्हणून बंद झाली.

३. २५ मार्च २०२५ पासून एकमेव उपकंपनीतील गुंतवणुकीच्या विक्रीमुळे, कंपनीला आता ३० सप्टेंबर २०२५ रोजी संपलेल्या तिमाहीतील फक्त स्वतंत्र वित्तीय निष्कर्ष सादर करावे लागतील. त्यानुसार, ३० सप्टेंबर २०२४ रोजी संपलेल्या तिमाही आणि ३१ मार्च २०२५ रोजी संपलेल्या वर्षासाठी तुलनात्मक स्वतंत्र विभाग माहिती वैधानिक लेखापरीक्षकांकडून मर्यादित पुनरावलोकनाच्या अधीन नव्हती आणि व्यवस्थापनाने ती संकलित केली आहे, कारण कंपनीने त्यावेळी एकत्रित विभाग निष्कर्ष प्रकाशित केले होते जे अशा पुनरावलोकनाच्या अधीन होते.

४. निष्कर्षांच्या अधिक तपशिलासाठी, कंपनीच्या संकेतस्थळ www.jyothylabs.com येथे इन्व्हेस्टर सेंटर विभागाला आणि स्टॉक एक्स्चेंजचे संकेतस्थळ अर्थात www.nseindia.com आणि www.bseindia.com च्या कॉर्पोरेट सेक्शन अंतर्गत फायनान्शियल रिझल्ट सेक्शनला भेट द्या.



संचालक मंडळाकरिता आणि वतीने
एम. आर. ज्योती
अध्यक्ष आणि व्यवस्थापकीय संचालक
दिआयएन: ००५७१८२८

स्थळ : मुंबई
दिनांक : १२ नोव्हेंबर, २०२५